Abstract: Clinical data suggest that only a subgroup of non-small cell lung cancer (NSCLC) patients has long-term benefits after front-line platinum-based therapy. We prospectively investigate whether KRAS status and DNA polymerase β expression could help identify patients responding to platinum compounds. Prospectively enrolled, advanced NSCLC patients treated with a first-line regimen containing platinum were genotyped for KRAS and centrally evaluated for DNA polymerase β expression. Overall survival (OS), progression-free survival (PFS), and the objective response rate (ORR) were recorded. Patients with KRAS mutations had worse OS (hazard ratio (HR): 1.37, 95% confidence interval (95% CI): 0.70–2.27). Negative DNA polymerase β staining identified a subgroup with worse OS than patients expressing the protein (HR: 1.43, 95% CI: 0.57–3.57). The addition of KRAS to the analyses further worsened the prognosis of patients with negative DNA polymerase β staining (HR: 1.67, 95% CI: 0.52–5.56). DNA polymerase β did not influence PFS and ORR. KRAS may have a negative role in platinum-based therapy responses in NSCLC, but its impact is limited.
DNA polymerase β, when not expressed, might indicate a group of patients with poor outcomes. KRAS mutations in tumors not expressing DNA polymerase β further worsens survival. Therefore, these two biomarkers together might well identify patients for whom alternatives to platinum-based chemotherapy should be used.

**Keywords:** NSCLC; KRAS; DNA polymerase beta; platinum-based first-line

### 1. Introduction

Over the last 40 years, several million lung cancer patients have received platinum-based regimens, and despite the clinical use of an impressive variety of targeted agents, these drugs are still one of the main therapeutic options for certain patients [1]. Platinum compounds are also the best choice in first-line immunotherapy combinations [2]. However, despite the good impact of platinum-based therapies, only a small proportion of patients have durable benefits [3]. Therefore, biomarkers to explain the resistance mechanisms to platinum compounds are urgently needed.

*KRAS* mutations have long been considered potential biomarkers to predict the outcome of platinum-based chemotherapy in NSCLC [4]. The TAILOR trial data shed light on the possibility that there was a small negative prognostic effect of *KRAS* mutations in advanced NSCLC patients treated with a platinum-based doublet when EGFR-mutant patients were excluded from the analysis [5].

Platinum adducts are repaired by different DNA repair systems. The Fanconi anemia (FA) pathway is thought to coordinate these systems, including homologous recombination (HR), nucleotide excision repair (NER), and translesion synthesis (TLS) repair [6,7]. Other DNA repair systems, such as base excision repair (BER), are involved in cisplatin-induced DNA damage, but so far, they have been assigned only a marginal role in repairing this damage [8].

Our group recently reported in a preclinical study that DNA polymerase β, an important component of the BER pathway, could be involved in platinum-based chemotherapy responses. Our results suggested a different pattern of sensitivity/resistance to cisplatin, dependent on *KRAS* mutational status [9].

The present work explores whether DNA polymerase β, alone or in combination with *KRAS* mutational status, can identify tumors with different abilities to respond to platinum compounds. This is the first study to prospectively assess the combined role of the selected biomarkers to identify patients who could benefit from platinum-based therapy.

### 2. Material and Methods

#### 2.1. Study Population and Samples

The Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy), the Regina Elena National Cancer Institute (Rome, Italy), the Hospital Papa Giovanni XXIII (Bergamo, Italy), and the Metropolitan and Attikon Hospitals (Athens, Greece) were the centers involved. Consecutive patients with metastatic NSCLC who received platinum-based chemotherapy in combination with either vinorelbine, gemcitabine, or pemetrexed, according to the physician’s choice, as first-line therapy between February 2014 and April 2017 were included in the BioRaRe prospective multicenter trial.

All patients had an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) between 0 and 2 and were at least 18 years of age. Exclusion criteria included any evidence of serious comorbidities that the investigator judged as a contraindication to the participation in the study, pregnancy, and breast-feeding.

Patients evaluable for tumor response according to the RECIST 1.1 criteria were examined, and their demographics and clinical and pathological characteristics were retrieved. E-CRF and medical records were used to collect data.
The study was approved by the Fondazione IRCCS Istituto Nazionale dei Tumori Institutional Review Board (INT18/13) and conducted according to the Declaration of Helsinki ethical principles for medical research involving human subjects. All patients gave signed written informed consent.

2.2. Mutational Analysis

*KRAS* mutational status was determined by Sanger sequencing at each center, following the protocol already used in a clinical trial by our group [10]. Briefly, DNA extraction was performed on histological tumor specimens by using standard phenol–chloroform procedure after macro/microdissection in order to recover most of the cancer cells and to reduce contamination by normal ones. DNA preparations were verified for their concentration and quality by spectrophotometric measurement. Genomic DNAs were amplified by polymerase chain reaction (PCR) using high-fidelity Taq polymerase and specific primers encompassing intronic regions for *KRAS* exons 2–4. PCR products were then analyzed electrophoretically on agarose gel, and automated bidirectional sequencing was performed using BigDye Terminator chemistry. Sequences were then automatically compared with wild-type *KRAS* gene profiles by software analysis to assess the presence of possible mutations.

2.3. Immunohistochemical Analysis (IHC)

IHC was done centrally on single slides at the Fondazione Filarete, as previously reported [11]. Sections were immune-stained with anti-DNA polymerase \( \beta \) antibody ab26343 (Abcam, Cambridge, UK), and incubated with biotinylated secondary goat anti-rabbit antibody (VC-BA-1000-MM15, Vector Laboratories, Burlingame, CA, USA). Sections were labeled by the avidin–biotin–peroxidase (ABC) procedure with a commercial immunoperoxidase kit (VECTASTAIN Elite ABC-Peroxidase Kit Standard, VC-PK-6100-KI01, Vector Laboratories, Burlingame, CA, USA). The immune reaction was visualized with 3,3′-diaminobenzidine peroxidase DAB substrate kit (VC-SK-4100-KI01, Vector Laboratories, Burlingame, CA, USA) substrate and sections were counterstained with Mayer’s hematoxylin. Figure S1 shows representative images of negative and positive DNA polymerase \( \beta \) staining.

A semiquantitative H-score (percentage of positive tumoral cells x intensity: \( 0 = \) negative, \( 1 = \) slight, \( 2 = \) moderate, \( 3 = \) strong) was calculated independently by two pathologists. In case of disagreement, a third opinion was requested.

2.4. Outcomes

The primary outcome of the study was progression-free survival (PFS). Secondary outcomes were objective response rate (ORR) and overall survival (OS). PFS was defined as the time from the start of the platinum-based first-line therapy to the date of progression or death from any cause, whichever came first. ORR was defined as the proportion of patients with a complete or partial response to treatment. OS was defined as the time from the platinum-based first-line therapy to the date of death from any cause.

2.5. Statistical Methods

Chi-squared and Kruskal–Wallis tests were used to analyze the relations between the DNA polymerase \( \beta \) H-score (Pol\( \beta \)) and categorical clinical variables. The Spearman correlation coefficient was used to measure the correlation between Pol\( \beta \) and continuous clinical variables. Pol\( \beta \) was analyzed as a continuous and dichotomous variable (Pol\( \beta = 0 \) as negative and Pol\( \beta > 0 \) as positive).

Patients who had not died or had no disease progression were censored at their last available information on status. Survival curves were calculated with the Kaplan–Meier method and tested by the log-rank test. Cox proportional hazard models were used to analyze the impact of DNA polymerase \( \beta \) on PFS and OS, adjusting for clinical and pathological characteristics such as ECOG-PS, age, histology, smoking, therapy, and, only for OS, immunotherapy. Results were expressed as hazard ratios (HRs) with their 95% confidence intervals (95% CIs).
The impact of DNA polymerase β on ORR was analyzed with logistic regression models and expressed as odds ratios (ORs) with their 95% CIs, while for dichotomized analysis, the chi-square test was used. A subgroup analysis was done for patients with both Polβ and KRAS mutational status available.

All statistical tests were two-sided, and \( p < 0.05 \) was considered statistically significant. Statistical analyses were done using SAS version 9.4 (SAS Institute, Cary, NC, USA).

3. Results

Of the 120 patients registered in the trial with material available, 109 had a DNA polymerase β H-score (Polβ) and 74 had both Polβ and KRAS mutational status. Figure 1 reports the flowchart of the study.

![Figure 1](image)

**Figure 1.** CONSORT diagram showing the flow of participants.

The main demographic characteristics of the population (\( n = 109 \)) and the relationships between characteristics and Polβ are reported in Table 1.

3.1. Progression-Free Survival

The median PFS was, respectively, 5.9 and 7.2 months in the mutated (mut) and wild-type (wt) KRAS groups (adjusted HR mut vs. wt: 1.09, 95% CI: 0.56–2.08, \( p = 0.815 \)).

Polβ, considered a continuous variable, did not have any significant impact on PFS in a multivariable Cox model. HR was 0.99 for each 10-unit increment of the score, with 95% CI 0.97–1.02 and \( p = 0.579 \). The inclusion of KRAS mutational status in the statistical model did not modify the impact of Polβ on progression or death risk (HR: 0.99, 95% CI: 0.96–1.02, \( p = 0.501 \)). Considering Polβ as a dichotomous variable, median PFS were, respectively, 4 and 6.3 months for negative (neg) and positive (pos) staining. The absence or presence of DNA polymerase β had no impact on the risk of PFS, considering the multivariable models, either including KRAS status or not in the analysis (HR pos vs. neg: 1.10, 95% CI: 0.44–2.70, \( p = 0.847 \); HR pos vs. neg: 1.08, 95% CI: 0.49–2.38, \( p = 0.857 \)). Detailed results of the multivariable analysis for PFS are reported in Table 2, and the Kaplan–Meier curves for PFS are shown in Figure 2A. The forest plot in Figure 2B graphically shows the effect of KRAS status on the relationship between Polβ and PFS.
3.2. Overall Survival

The median OS was, respectively, 12.4 and 20.5 months in the mutated and wild-type KRAS groups (adjusted HR mut vs. wt: 1.27, 95% CI: 0.70–2.27, \( p = 0.441 \)).

Polβ, analyzed as a continuous variable, had no impact on survival in the multivariable models including KRAS status or not (HR: 0.99, 95% CI: 0.96–1.01, \( p = 0.39 \); HR = 0.99, 95% CI: 0.95–1.02, \( p \)-value = 0.388).

Patients who were negative for DNA polymerase β staining had a median OS of 11.6 months compared to 20.6 months in the positive group. The absence of DNA polymerase β caused a worse but not statistically significant OS compared to DNA polymerase β-expressing patients (HR pos vs. neg: 1.43, 95% CI: 0.57–3.57, \( p = 0.439 \)). With the inclusion of KRAS mutational status in the statistical model, the effect on survival with Polβ was stronger (HR pos vs. neg: 1.67, 95% CI: 0.52–5.56, \( p = 0.386 \)). The results of the multivariate analyses for OS are reported in Table 3. Kaplan–Meier curves for OS, reported in Figure 3A,B, show the effect of KRAS status on the relationship between Polβ and OS.

**Table 1.** Baseline characteristics of patients (\( n = 109 \)) and their relation with Polβ as a continuous or dichotomous variable. Pos, positive; neg, negative.

|                          | \( n \) (%) | \( p \) Polβ Continuous | \( p \) Polβ pos vs. neg |
|--------------------------|-------------|-------------------------|------------------------|
| Age of diagnosis Median(Q1-Q3) | 66.8 (60.0–71.4) | 0.448 * | 0.788 † |
| Gender                   |              |                         |                        |
| Male                     | 70          | 65.4                    | 0.717 †               | 0.366 ** |
| Female                   | 37          | 34.6                    |                        |          |
| Missing                  | 2           |                         |                        |          |
| ECOG-PS                  |              |                         |                        |
| 0                        | 78          | 81.3                    | 0.157 †               | 0.443 ** |
| 1                        | 17          | 17.7                    |                        |          |
| 2                        | 1           | 1                       |                        |          |
| Missing                  | 13          |                         |                        |          |
| Smoking                  |              |                         |                        |
| Never                    | 21          | 20                      | 0.618 †               | 1.000 ** |
| Former smokers           | 42          | 40                      |                        |          |
| Smokers                  | 42          | 40                      |                        |          |
| Missing                  | 4           |                         |                        |          |
| Stage at diagnosis       |              |                         |                        |
| IIIB                     | 28          | 26.2                    | 0.038 †               | 0.507 ** |
| IV                       | 79          | 73.8                    |                        |          |
| Missing                  | 2           |                         |                        |          |
| Histotype                |              |                         |                        |
| Adenocarcinoma           | 90          | 82.6                    | 0.291 †               | 0.184 ** |
| Squamous                 | 17          | 15.6                    |                        |          |
| Other                    | 2           | 1.8                     |                        |          |
| Platinum-based therapy   |              |                         |                        |
| Cisplatin                | 33          | 34.7                    | 0.726 †               | 0.486 ** |
| Carboplatin              | 62          | 65.3                    |                        |          |
| Missing                  | 14          |                         |                        |          |
| Immunotherapy            |              |                         |                        |
| No                       | 62          | 58.5                    | 0.248 †               | 0.352 ** |
| Yes                      | 44          | 41.5                    |                        |          |
| Missing                  | 3           |                         |                        |          |
| Polβ                     |              |                         |                        |
| Median(Q1-Q3)            | 160.0 (60.0–200.0) | -                      | -                      |          |
| negative                 | 13          | 11.9                    | -                      | -        |
| positive                 | 96          | 88.1                    | -                      | -        |
| KRAS                     |              |                         |                        |
| Mutated                  | 35          | 47.3                    | 0.053 †               | 0.125 ** |
| Wild-Type                | 39          | 52.7                    |                        |          |
| Missing                  | 35          |                         |                        |          |

At a median follow-up of 18.8 months (Q1–Q3: 8.3–48.9), there were 90 progressions, 62 deaths, and 100 deaths or progressions. Q1–Q3: first–third quartile, pos: positive, neg: negative; †: Kruskal–Wallis test, *: Spearman correlation, **: Fisher test.
Table 2. Multivariable Cox models adjusted for ECOG-PS, age, histology, smoking, and therapy for progression-free survival, considering Polβ continuous or Polβ positive vs. negative. Pos, positive; neg, negative.

|                      | Polβ Continuous | Polβ pos vs. neg |
|----------------------|-----------------|------------------|
|                      | HR (95% CI)     | p                | HR (95% CI)    | p                |
| Polβ (10-unit increment) | 0.99 (0.97–1.02) | 0.579 | - | - |
|                      | Polβ            |                  |                |
| Positive             | -               | -                | reference      |                  |
| Negative             | -               | -                | 1.07 (0.49–2.38) | 0.857 |
| Age at metastasis diagnosis (5 years increment) | 0.82 (0.72–0.94) | 0.005 | 0.82 (0.72–0.95) | 0.006 |
| Histology            |                  |                  |
| Adenocarcinoma       | reference        | reference        |                |                  |
| Squamous             | 1.10 (0.60–2.03) | 0.755 | 1.12 (0.60–2.10) | 0.728 |
| Nos or other         | 2.26 (0.27–18.6) | 0.449 | 2.34 (0.28–19.5) | 0.432 |
| Smoke                |                  |                  |
| Never                | reference        | reference        |                |                  |
| Previous             | 1.25 (0.69–2.26) | 0.463 | 1.27 (0.70–2.29) | 0.434 |
| Current              | 0.79 (0.40–1.56) | 0.495 | 0.81 (0.41–1.59) | 0.543 |
| ECOG-PS              |                  |                  |
| 1.51 (0.78–2.94)     | 0.223 | 1.51 (0.76–3.00) | 0.244 |
| Therapy              |                  |                  |
| Cisplatin            | reference        | reference        |                |                  |
| Carboplatin          | 1.73 (1.02–2.92) | 0.041 | 1.69 (1.01–2.85) | 0.046 |

Table 3. Multivariable Cox models adjusted for ECOG-PS, age, histology, smoking, therapy, and immunotherapy for OS, considering Polβ continuous and Polβ positive or negative. Pos: positive, neg: negative.

|                      | Polβ Continuous | Polβ pos vs. neg |
|----------------------|-----------------|------------------|
|                      | HR (95% CI)     | p                | HR (95% CI)    | p                |
| Polβ (10-unit increment) | 0.99 (0.96–1.01) | 0.390 | - | - |
|                      | Polβ            |                  |                |
| Positive             | -               | -                | reference      |                  |
| Negative             | -               | -                | 1.43 (0.57–3.57) | 0.439 |
| Age at metastasis diagnosis (5 years increments) | 0.87 (0.75–1.01) | 0.066 | 0.87 (0.75–1.01) | 0.065 |
| Histology            |                  |                  |
| Adenocarcinoma       | reference        | reference        |                |                  |
| Squamous             | 0.94 (0.46–1.95) | 0.877 | 0.98 (0.47–2.06) | 0.960 |
| Nos or other         | 7.67 (0.80–70.6) | 0.072 | 8.86 (0.94–83.3) | 0.056 |
| Smoke                |                  |                  |
| Never                | reference        | reference        |                |                  |
| Previous             | 2.65 (1.15–6.12) | 0.022 | 2.76 (1.21–6.30) | 0.016 |
| Current              | 1.58 (0.61–4.11) | 0.350 | 1.63 (0.63–4.26) | 0.316 |
| ECOG-PS              |                  |                  |
| 1.18 (0.48–2.90)     | 0.724 | 1.12 (0.44–2.87) | 0.812 |
| Therapy              |                  |                  |
| Cisplatin            | reference        | reference        |                |                  |
| Carboplatin          | 1.74 (0.94–3.21) | 0.075 | 1.70 (0.93–3.12) | 0.084 |
| Immunotherapy        |                  |                  |
| No                   | reference        | reference        |                |                  |
| Yes                  | 0.57 (0.32–1.03) | 0.063 | 0.55 (0.31–0.98) | 0.041 |
Figure 2. (A) Kaplan–Meier curves for PFS according to the positive or negative DNA polymerase β staining. (B) Effect of KRAS status on the relationship between Polβ and PFS adjusted for ECOG-PS, age, histology, smoking, and therapy.
for OS, reported in Figure 3A,B, show the effect of KRAS status on the relationship between Polβ and OS.

Figure 3. (A) Kaplan–Meier curves for OS, according to the positive or negative DNA polymerase β staining. (B) Effect of KRAS status on the relationship between Polβ and PFS adjusted for ECOG-PS, age, histology, smoking, therapy, and immunotherapy.

3.3. Overall Response Rate

There were no differences between the DNA polymerase β negative and positive staining groups, or among different Polβ as a continuous variable in ORR to platinum-based first-line therapy (Table 4).

Table 4. Objective response rates by DNA Polymerase β H-score (Polβ). CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

|          | Polβ neg n = 12 | Polβ pos n = 64 | Chi-Squared Test | Logistic Regression Model |
|----------|-----------------|-----------------|------------------|--------------------------|
| CR + PR  | 4 (33.3)        | 23 (35.9)       | Chi = 0.03       | OR = 1.002               |
| 95% CI   | 34.9–90.1       | 51.1–75.7       | Df = 1           | 95% CI = 0.997–1.006     |
| SD + PD  | 8 (66.7)        | 41 (64.1)       | p = 0.864        | p = 0.505                |
| 95% CI   | 9.9–65.1        | 24.3–48.9       |                  |                          |

4. Discussion

KRAS mutations have often been investigated as possible biomarkers for selecting chemotherapy, but results have varied, casting doubt on the true utility of this protein. In a previously published randomized prospective trial from our group, an analysis of 247 patients showed that those carrying KRAS mutations and treated with a first-line platinum-based regimen had worse PFS than patients with wild-type KRAS [5]. The present study detected a not-statistically-significant effect for OS,
KRAS-mutated patients having a worse prognosis than KRAS wild-type patients. A possible explanation, although the trend is in line with previous observations, is that the statistical power of this cohort of patients was half that in our earlier study, where KRAS status was significantly associated with survival. On the other hand, the LACE-Bio pooled analysis, including data of 1543 patients participating in four clinical trials, showed that there is no difference in terms of outcomes in early-stage lung cancer patients with either wild-type or mutated KRAS [12]. Our different result may suggest that KRAS mutations could play different roles in early and advanced disease. In advanced stages, KRAS could be a condition necessary, but not sufficient, to explain a more aggressive phenotype.

There is preclinical evidence that KRAS and its mutated versions modulate DNA repair, hence the cellular response to genotoxic agents. Oncogenic RAS can inactivate BRCA-1 dependent homologous recombination (HR) by favoring the dissociation of BRCA-1 from chromatin [13]. Moreover, activated KRAS can suppress the expression of DNA repair genes (including BRCA1, BRCA2, EXO-1, and TP53) [14]. In leukemic cells, mutant KRAS promoted the upregulation of components of the alternative nonhomologous end-joining (NHEJ) pathway, such as DNA ligase IIIα, PARP1, and XRCC1, and the inhibition of the alternative NHEJ pathway selectively sensitized KRAS-mutated cells to chemotherapy [15].

Our group also suggested KRAS-dependent specific alterations in the BER system, where we found DNA polymerase β as a possible selection factor. We demonstrated at the preclinical level that DNA polymerase β could play a role in the response to cisplatin-based chemotherapy, and the data indicated a pattern of sensitivity or resistance depending on the KRAS mutational status [9]. These findings support the hypothesis that the combination of mutant-KRAS status with DNA repair could be a predictive biomarker for response to platinum-based therapy.

On the basis of these assumptions, we planned a translational study to clinically validate KRAS and DNA polymerase β as “biomarkers” for poor response and outcome to platinum-based first-line chemotherapy. We investigated DNA polymerase β as a possible selection marker, alone or in combination with KRAS status. DNA polymerase β expression, summarized in the H-score and considered as a continuous variable, was meaningless to both PFS and OS, alone or with KRAS.

When we compared negative or positive DNA polymerase β staining patients, we detected an interesting, though not statistically significant, difference: OS patients negative for DNA polymerase β staining had worse outcomes than the positive staining group. This result was confirmed even when KRAS status was considered in the analysis.

These data, although interesting and calling for further analysis, are not supported by the literature, where DNA polymerase β upregulation was described as causing resistance to cisplatin in an ovarian cancer model [16]. In a colorectal cancer model expressing high levels of DNA polymerase β, cisplatin was ineffective compared to the same model in which DNA polymerase β was downregulated. In the same paper, 5-year OS curves showed that patients with high DNA polymerase β expression had a significantly poorer prognosis than those with low expression [17]. However, DNA polymerase β has been investigated as a selection marker in very few, only retrospective studies, and our is the first attempt to investigate it, prospectively, in NSCLC.

A recent report suggests that if cells are not able to repair DNA single-strand break lesions through BER (as should be the case here for cells negative for DNA polymerase β), these lesions are channeled to the HR system [18]. We do not know whether this is also true for cisplatin-induced DNA lesions and whether these patients have HR alterations, but it does suggest an intriguing explanation for the worse outcome observed in DNA polymerase β-negative patients.

To our knowledge, this is the first investigation of the role and value of DNA polymerase β, alone or in combination with KRAS status, as a marker of response to platinum-based therapy in NSCLC. Besides the results, this paper also stimulates the idea to further investigate the combination of biomarkers that indicate how different biological pathways coexist or work together in those scenarios, where no single biomarker has been shown to have strong value.
In conclusion, KRAS may have a negative role in platinum-based therapy responses in NSCLC, but its impact is limited. The absence of DNA polymerase β might indicate a group of patients with poor outcomes compared to patients positively staining for this protein. In addition, a mutated form of KRAS in tumors not expressing DNA polymerase β further worsens survival. Therefore, these two biomarkers together might well identify patients for whom alternatives to platinum-based chemotherapy should be used.

Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/8/2438/s1, Figure S1: Negative and positive DNA polymerase β staining tissues magnified 400X.

Author Contributions: Conceptualization, H.L., M.B., M.C.G., and M.M. (Mirko Marabese); data curation, S.M.; formal analysis, M.F.A. and E.R.; funding acquisition, M.C.G. and M.M. (Mirko Marabese); investigation, M.G., H.L., E.C., G.L.R., F.L.C., A.C.B., A.P., M.M. (Michele Milella), A.F., M.D.M., P.R., S.M., G.N., M.B., M.C.G., and M.M. (Mirko Marabese). All authors have read and agreed to the published version of the manuscript.

Funding: The research leading to these results received funding from Transcan Era-Net JTC-2011 project ID 40 (M.C.G.) and AIRC under MFAG 2016 project ID 18386 (M.M. (Mirko Marabese)).

Conflicts of Interest: M.C.G. reports grants from AstraZeneca, Bristol-Myers Squibb, MSD Oncology, Roche, Takeda, Incyte, Lilly, Merck, Pfizer, Clovis, Merck Serono, Bayer, Spectrum Pharmaceuticals, F. Hoffmann-La Roche, Blueprint Medicine; personal fees from AstraZeneca, Bristol-Myers Squibb, MSD Oncology, Novartis, Roche, Takeda, Tiziana Life Sciences, Celgene, Incyte, Boehringer Ingelheim, Otsuka Pharma, Bayer, Inivata, Sanofi-Aventis, SeaGen International GmbH; non-financial support from AstraZeneca, Roche, Pfizer, F. Hoffmann-La Roche. The remaining authors have nothing to disclose.

References
1. Schirrmacher, V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int. J. Oncol. 2018, 54, 407–419. [PubMed]
2. Gandhi, L.; Rodriguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; D’omine, M.; Clingan, P.; Hochmair, M.J.; Powell, S.F.; et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 378, 2078–2092. [CrossRef] [PubMed]
3. Schmidt, E.V. Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. Semin. Immunopathol. 2019, 41, 21–30. [CrossRef] [PubMed]
4. Piva, S.; Ganzinelli, M.; Garassino, M.C.; Caiola, E.; Farina, G.; Brogginii, M.; Marabese, M. Across the universe of K-RAS mutations in non-small-cell-lung cancer. Curr. Pharm. Des. 2014, 20, 3933–3943. [CrossRef] [PubMed]
5. Marabese, M.; Ganzinelli, M.; Garassino, M.C.; Shepherd, F.A.; Piva, S.; Caiola, E.; Macerelli, M.; Bettini, A.; Lauricella, C.; Floriani, I.; et al. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. Oncotarget 2015, 6, 34014–34022. [CrossRef] [PubMed]
6. Deans, A.J.; West, S.C. DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 2011, 11, 467–480. [CrossRef] [PubMed]
7. Haynes, B.; Saadat, N.; Myung, B.; Shekhar, M.P. Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance. Mutat. Res.-Rev. Mutat. Res. 2015, 763, 258–266. [CrossRef] [PubMed]
8. Jung, Y.; Lippard, S.J. Direct cellular responses to platinum-induced DNA damage. Chem. Rev. 2007, 107, 1387–1407. [CrossRef] [PubMed]
9. Caiola, E.; Salles, D.; Frapolli, R.; Lupi, M.; Rotella, G.; Ronchi, A.; Garassino, M.C.; Mattschas, N.; Colavecchio, S.; Brogginii, M.; et al. Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget 2015, 6, 30072–30087. [CrossRef] [PubMed]
10. Garassino, M.C.; Martelli, O.; Brogginii, M.; Farina, G.; Veronese, S.M.; Ruilli, E.; Bianchi, F.; Bettini, A.; Longo, F.; Moscelli, L.; et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): A randomised controlled trial. Lancet Oncol. 2013, 14, 981–988. [CrossRef]
11. Marabese, M.; Marchini, S.; A Sabatino, M.; Polato, F.; Vihknaskaya, F.; Marrazzo, E.; Riccardi, E.; Scanziani, E.; Brogginii, M. Effects of inducible overexpression of DNp73α on cancer cell growth and response to treatment in vitro and in vivo. Cell Death Differ. 2005, 12, 805–814. [CrossRef] [PubMed]
12. Shepherd, F.A.; Domerg, C.; Hainaut, P.; Jänne, P.A.; Pignon, J.-P.; Graziano, S.; Douillard, J.-Y.; Brambilla, E.; Le Chevalier, T.; Seymour, L.; et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non–small-cell lung cancer in four trials of adjuvant chemotherapy. *J. Clin. Oncol.* 2013, 31, 2173–2181. [CrossRef] [PubMed]

13. Tu, Z.; Aird, K.M.; Bitler, B.G.; Nicodemus, J.P.; Beeharry, N.; Xia, B.; Yen, T.J.; Zhang, R. Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from Chromatin, Inhibit DNA repair, and promote senescence. *Dev. Cell* 2011, 21, 1077–1091. [CrossRef] [PubMed]

14. Tsunoda, T.; Takashima, Y.; Fujimoto, T.; Koyanagi, M.; Yoshida, Y.; Doi, K.; Tanaka, Y.; Kuroki, M.; Sasazuki, T.; Shirasawa, S. Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model. *Neoplasia* 2010, 12, 397–404. [CrossRef] [PubMed]

15. Hahnel, P.S.; Enders, B.; Sasca, D.; Roos, W.P.; Kaina, B.; Bullinger, L.; Theobald, M.; Kindler, T. Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy. *Blood* 2014, 123, 2355–2366. [CrossRef] [PubMed]

16. Bergoglio, V.; Canitrot, Y.; Hogarth, L.; Minto, L.; Howell, S.B.; Cazaux, C.; Hoffmann, J.-S. Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: Impact on sensitivity towards antitumor agents. *Oncogene* 2001, 20, 6181–6187. [CrossRef] [PubMed]

17. Iwatsuki, M.; Mimori, K.; Yokobori, T.; Tanaka, F.; Tahara, K.; Inoue, H.; Baba, H.; Mori, M. A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer. *J. Surg. Oncol.* 2009, 100, 261–266. [CrossRef] [PubMed]

18. Giovannini, S.; Weller, M.C.; Repmann, S.; Moch, H.; Jiricny, J. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage. *Nucleic Acids Res.* 2019, 47, 9132–9143. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).